Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Exciting news! 🌟 Tomorrow at 7 am CST, Imagion presents groundbreaking data from our IBI10103 Phase I Study demonstrating the safety and clinical feasibility of Molecular MRI with #MagSense HER2 Imaging Agentat #SABCS23. Request the data: https://t.co/FNCdufN13G #Innovation $IBX pic.twitter.com/oS2rSuhWRC
— Manhattan Scientific (@mhtxscientifics) December 6, 2023
Once IBX comes out with their version there will be no misdiagnosed views...
"Despite Prenuvo's focus on preventive health, many radiologists say full-body MRI scanning can do more harm than good. False positives and detection of benign abnormalities could send patients down a path of unnecessary follow-up tests and interventions." Aug 18, 2023
A healthy new presentation by new IBX CEO here...
Investors update
Newsletter Highlights:
Clinical data and expert review triggers commercial partner outreach efforts
MRI utility drives new IP and AI/ML efforts
Upcoming events and a recap on key media coverage
A Message From the CEO
As we noted in our 2022 Annual Report, last year was a momentous year having reported results from the first cohort of subjects in the MagSense® HER2 Phase 1 study at a global breast cancer meeting and presenting our prostate cancer imaging agent at an imaging conference.
That momentum has continued in the first quarter of this year with the independent review we reported at the beginning of February and the recent news of our communications with the FDA related to our plans to file an IND and proceed with a multi-site study in the U.S. for the MagSense® HER2 imaging agent.
In this newsletter, we are pleased to share some of the additional activities we are undertaking to keep the momentum going.
We look forward to keeping all our stakeholders apprised of the work we are doing to change the way we look at cancer with our MagSense® molecular imaging technology.
Bob Signature 600px (2)
Strategic Partnering Data Room
Our MagSense® imaging agents could be the first-of-its-kind molecular imaging solution for MRI. By changing current practice in medical imaging to include the sensitive and selective detection of cancer cells without using radiation, Imagion’s technology could significantly improve cancer diagnosis and patient care.
Now that our MagSense® imaging agent for HER2 breast cancer detection is progressing towards Phase 2 and our technology is showing positive preclinical results in other areas of high unmet need, including prostate cancer and ovarian cancer, we have a substantial value proposition for the medical imaging sector and are now well-placed to initiate discussions around strategic options with potential commercial partners. Our current pipeline represents a projected global market opportunity of ~ $5Billion* for Imagion and our partner(s).
To facilitate the process, we have established a secure data room where we can share confidential information related to the MagSense® HER2 program as well as our growing pipeline of imaging agents and will begin outreach programs to potential partners in an effort to gauge market interest in our technology.
Parties interested in partnering with Imagion to commercialize our MagSense® molecular imaging technology can contact us via partnering@imagionbio.com.
* Total available market estimates based on market data of current testing and a projected MagSense® price of $1200.
MRI Utility Drives New Areas for IP and Analytics
Data from the MagSense® HER2 Phase 1 study and internal R&D programs have opened new opportunities for Imagion to file for intellectual property and are driving efforts to investigate how analytical methods in Artificial Intelligence (AI) and Machine Learning (ML) might be applied to improve the clinical utility of the MagSense® imaging tests.
A provisional patent application has been filed related to the image pattern(s) associated with presence of the MagSense® targeted imaging agent. This new IP would extend our proprietary position for our magnetic nanoparticles across both magnetic relaxometry and magnetic resonance imaging, providing broader protection against other imaging agents that might try to replicate targeted detection by MRI. While there is no guarantee that the patent will issue, the new IP would provide significant value to Imagion and its commercial partners, carving out a unique space in the medical imaging landscape.
Additionally, the Company has initiated a project with a 3rd party with expertise in image analysis methods including AI and ML, to determine if algorithmic solutions could be applied to the MRI scans resulting from a MagSense® test to improve interpretability. Data from the Phase 1 study has informed the initial investigations and the Company is now looking into how algorithmic solutions may help drive improvements in image acquisition in the Phase 2 study. If algorithmic solutions can be applied, it would open the opportunity for the MagSense® imaging agents to be sold with an associated Software as a Medical Device (SaaMD) solution to aid radiologists in the interpretation of the MagSense® test results.
Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company would look to apply the intellectual property and image analysis solutions broadly across the portfolio of MagSense® nanoparticle imaging agents.
In the end, it will still be produced by FWM, under the direction of Terry C Lowe, who has been working with the Czech company who is currently now producing the only other nanotitanium orthodontal work in the world...
https://english.radio.cz/ostrava-scientists-can-make-worlds-strongest-titanium-alloy-8194569
Try doing some real reading on the many other metals and many other applications that FWM has been clandestinely working on with MHTX for well over the past 5 years.
https://link.springer.com/article/10.1007/s11837-020-04195-4
How about this from Terry C Lowe's current employment LinkedIn page...
Co-founder and President
Metallicum Inc.
May 2001 - Mar 2012, 10 years 11 months
Santa Fe, New Mexico Area
Co-founded and led Metallicum Inc. for 11 years. Developed and commercialized nanostructured metals patents, mainly for orthopedic device applications. Merged Metallicum Inc. into Manhattan Scientifics Inc. in 2008 and led transfer of its nanometals technology to establish full scale production with a large USA-based manufacturing partner.
Why have six of the eight scientists who were working on this only 2 years back, at Fort Wayne Metals, were from CSM ?
https://www.sciencedirect.com/science/article/abs/pii/S0167577X21013288#:~:text=Continuous%20Equal%20Channel%20Angular%20Pressing%20(C%2DECAP)%20is%20a,mechanical%20properties%20of%20many%20alloys.
The Future of Magnetic Relaxometry (MRX)
The Company plans to continue to develop the proprietary detection technology, known as the magnetic
relaxometry (MRX) in collaboration with academic and industry partners, focusing on a new generation of
small magnetic sensors that could enable the use of magnetic relaxometry, (Magsense), in the doctor’s office.
In the future MRX could be a game-changing instrument that would allow non-invasive cancer diagnosis at
the first point of care, e.g. at the urologist or OB/Gyn or general practitioner.
From the Announcements Highlights :
Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance Imaging (MRI).
Further in Paragraph 5 :
The confirmation by the panel of the Company’s assessment that cancer detection can be achieved when using the MagSense® imaging agent with MRI has significant implications for the Company.
Refer Pge 2 Paragraph 1 :
“We will continue to refine our proprietary relaxometry technology but can now confidently shift our resources to developing our nanoparticles for use with MRI, a ubiquitous imaging modality used in hospitals and radiology clinics throughout the world. We believe this will be more attractive for strategic partners and more likely for us to achieve commercial success sooner.” Since all MagSense® targeted imaging agents use the same underlying magnetic nanoparticle technology, the Company now plans to prioritize the development of its MagSense® nanoparticle technology for use with mainstream clinical MRI scanners. (Later reference : there are 30,000 clinical grade MRI scanners globally)
IMO this good news announcement is the start of an SP turnaround as the market becomes aware of our potential. Further patient data will continue to build our support as it becomes available. Our commercialisation strategy is being revealed and Siemens involvement may be the next good news release.
A positive factual video and article...
https://themarketherald.com.au/imagion-biosystems-asxibx-accelerates-magsense-development-following-independent-review-2023-02-06/
IBX, some great news from an independent blinded review by a panel of expert breast cancer radiologists which has corroborated previously reported positive findings for the company’s MagSense diagnostic tech.
The company says that the radiologists confirmed that the “MagSense HER2 imaging agent produces a change in image contrast and that the contrast in nodes highly suspicious for tumour is distinctly different from the MR image contrast seen in non-involved nodes”.
“The outcome of the independent review is welcome news, indeed,” Imagion Biosystems CEO Bob Proulx said.
“We now have a clear indication that our MagSense magnetic nanoparticle technology could work with the existing medical imaging infrastructure to provide the clinical benefit to breast cancer patients we have been aiming for.
“This takes a lot of the technical risk out of the future and will significantly facilitate market entry by eliminating the need to design, make, sell, and support new machinery.”
It appears that IBX's Magsense is taking a quicker financial road to success by focusing on collaborating with powerhouses like , maybe Siemens MRI, while still continuing work on their own MRX technology independently. We'll know better after their presentation tomorrow...
https://imagionbiosystems.com/news/priority-path-to-market-for-magsense-technology/
I can't seem to get this Interview to appear on here, but simply copy and view this from 2 days ago...
executive interviews/robert proulx of imagion biosystems
A revised patent issued to IBX...
https://patents.justia.com/assignee/imagion-biosystems-inc
IBX now has 25 workers in San Diego. Did some research on which 10 have been added within last 6 months, 9 within last 1 to 2 years, 3 within 2 to 5 years and 3 since the founding of IBX. Some good news has to be coming.
New video with IBX progress Bob Proulx put out a few days ago.
https://themarketherald.com.au/imagion-biosystems-asxibx-reports-positive-first-magsense-breast-cancer-clinical-data-2022-12-08/
For those saying "only 6 patients"... Did you not read the announcement? The first cohort was 6 patients and the second cohort has already received consistent results with the first.
And from the collaboration agreement between PAB and IBX signed 6 months ago...
Dr. James Campbell, Patrys’ CEO and Managing Director. “The potential for our deoxymab antibodies to home in on a range of different cancer types due to their affinity for DNA is one of the properties that makes them so unique and opens up a range of different clinical applications for their use. We are very excited to be further leveraging the cancer-targeting ability of deoxymabs by partnering with Imagion and its innovative MagSense® imaging technology to potentially develop new ways to visualise and diagnose cancer. This is the first of multiple potential applications of our deoxymab platform, and while our focus is on advancing our novel cancer therapeutics to the clinic we are actively engaged in business development efforts for the broader platform to leverage theunique attributes of deoxymabs.”
From a recent email reply of James Campbell, (CEO to Patrys Limited)...
"As well as the DX1 advances, investors should keep an eye on DX3, and the fact that we are already working with other companies to explore delivery of different payloads. This could generate some non-dilutive cash for us as we push forward into the clinic"
Imagion Biosystems seeks an international patent here...
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022060924
IBX has just posted, (an hour ago), that they are looking for a Program Director to guide them through the many new cancer clinical trials they are about to start...
https://www.linkedin.com/mwlite/jobs/view/3307998188?referenceId=nrN10YKZQEiLnNJlPMRzDQ%3D%3D&eBP=JOB_SEARCH_ORGANIC
Nice article on IBX's potential...
https://themarketherald.com.au/imagion-biosystems-asxibx-big-things-come-in-nano-packages-2022-11-08/
Another nice video with Bob...
https://mobile.twitter.com/xrp_digigold/status/1584271595899871232/mediaviewer
"This is an important result that opens up a range of potential applications for Patrys and its development partners."
https://patrys.com/pat-dx3-crosses-blood-brain-barrier-in-healthy-animals/
For #BreastCancerAwarenessMonth, our team wanted to share stories about what motivates them to work with us, as we continually strive to provide earlier cancer detection methods to help save lives.#ThinkPink #WhyWeCare #IamAnImagioneer pic.twitter.com/S3Ta8HUGPH
— Imagion Biosystems (@imagionbio) October 12, 2022
Another informative link on where IBX is headed...
Good news for one of IBX's collaborators...
https://globalcancertechnology.com/news/